Trinity Capital provides $130M term loan facility to Candel Therapeutics

Health Care · United States · $130M ($50M drawn at closing)

Trinity Capital entered a five-year, $130 million, four-tranche term loan facility with Nasdaq-listed Candel Therapeutics, with an initial $50 million tranche drawn at closing to support the company ahead of a potential commercial launch in early localized prostate cancer.